Azenosertib + Niraparib
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Trial Timeline
Jan 27, 2022 → Jan 19, 2026
NCT ID
NCT05198804About Azenosertib + Niraparib
Azenosertib + Niraparib is a phase 1/2 stage product being developed by Zentalis Pharmaceuticals for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05198804. Target conditions include Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05198804 | Phase 1/2 | Completed |
Competing Products
20 competing products in Ovarian Cancer